Literature DB >> 8945620

Expression and tyrosine phosphorylation of EMS1 in human breast cancer cell lines.

D H Campbell1, A deFazio, R L Sutherland, R J Daly.   

Abstract

The EMS1 gene encodes an 80/85 kDa c-src substrate and localises with the CCND1 gene to chromosome 11q13. This locus is amplified in approximately 13% of human breast cancers. EMS1 gene amplification and expression were characterised in a panel of human breast cancer cell lines to determine at what levels expression is regulated. The degree of tyrosine phosphorylation of EMS1 protein was also determined and compared with the activity of src-family kinases. The EMS1 gene was amplified in 6 of 20 cell lines investigated: MDA-MB-134, -157, -175, -453, ZR-75-1 and MCF-7. In the MDA-MB-157 and MCF-7 cell lines, EMS1 was amplified in the absence of CCND1 gene amplification. EMS1 protein levels were increased relative to normal breast epithelial cells in 6 cell lines (ZR-75-1, MDA-MB-134, -175, 453, MCF-7 and BT-474). Of these, BT-474 is the only cell line that does not exhibit EMS1 amplification or increased EMS1 mRNA levels. EMS1 tyrosine phosphorylation was 3-fold higher in BT-474 and T-47D cells, which exhibited relatively high total src activity coupled with expression of both c-fyn and c-yes, than in MDA-MB-453 cells, which expressed only c-yes. Our results therefore demonstrate gene amplification to be the predominant mechanism underlying EMS1 over-expression in human breast cancer cell lines and identify tyrosine phosphorylation as a further level at which regulation of this protein may be perturbed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8945620     DOI: 10.1002/(SICI)1097-0215(19961115)68:4<485::AID-IJC14>3.0.CO;2-4

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  Cortactin in cell migration and cancer at a glance.

Authors:  Stacey M MacGrath; Anthony J Koleske
Journal:  J Cell Sci       Date:  2012-04-01       Impact factor: 5.285

2.  NEDD9 regulates actin dynamics through cortactin deacetylation in an AURKA/HDAC6-dependent manner.

Authors:  Varvara K Kozyreva; Sarah L McLaughlin; Ryan H Livengood; Robin A Calkins; Laura C Kelley; Anuradha Rajulapati; Ryan J Ice; Matthew B Smolkin; Scott A Weed; Elena N Pugacheva
Journal:  Mol Cancer Res       Date:  2014-02-26       Impact factor: 5.852

3.  Amplification and overexpression of the EMS 1 oncogene, a possible prognostic marker, in human hepatocellular carcinoma.

Authors:  Bao-Zhu Yuan; Xiaoling Zhou; Drazen B Zimonjic; Marian E Durkin; Nicholas C Popescu
Journal:  J Mol Diagn       Date:  2003-02       Impact factor: 5.568

4.  The "Spot 14" gene resides on the telomeric end of the 11q13 amplicon and is expressed in lipogenic breast cancers: implications for control of tumor metabolism.

Authors:  J T Moncur; J P Park; V A Memoli; T K Mohandas; W B Kinlaw
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

Review 5.  Cortactin signalling and dynamic actin networks.

Authors:  Roger J Daly
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

6.  Identification of single- and multiple-class specific signature genes from gene expression profiles by group marker index.

Authors:  Yu-Shuen Tsai; Kripamoy Aguan; Nikhil R Pal; I-Fang Chung
Journal:  PLoS One       Date:  2011-09-01       Impact factor: 3.240

7.  Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice.

Authors:  Agnes G S H van Rossum; Maaike P A van Bragt; Ellen Schuuring-Scholtes; Jan C M van der Ploeg; Johan H J M van Krieken; Philip M Kluin; Ed Schuuring
Journal:  BMC Cancer       Date:  2006-03-14       Impact factor: 4.430

8.  Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis.

Authors:  Md Kamrul Hasan; George F Widhopf; Suping Zhang; Sharon M Lam; Zhouxin Shen; Steven P Briggs; Barbara A Parker; Thomas J Kipps
Journal:  NPJ Breast Cancer       Date:  2019-10-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.